Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 19 studies | 42% ± 20% | |
peripheral blood | 18 studies | 34% ± 10% | |
lung | 17 studies | 30% ± 11% | |
intestine | 10 studies | 27% ± 13% | |
eye | 10 studies | 30% ± 10% | |
kidney | 8 studies | 27% ± 7% | |
heart | 5 studies | 25% ± 4% | |
lymph node | 5 studies | 31% ± 5% | |
liver | 5 studies | 40% ± 17% | |
bone marrow | 4 studies | 34% ± 10% | |
uterus | 4 studies | 37% ± 14% | |
breast | 4 studies | 25% ± 6% | |
adipose | 4 studies | 45% ± 18% | |
pancreas | 3 studies | 43% ± 19% | |
skin | 3 studies | 20% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 14832.88 | 459 / 459 | 100% | 68.98 | 1118 / 1118 |
esophagus | 100% | 16155.89 | 1445 / 1445 | 100% | 72.77 | 183 / 183 |
ovary | 100% | 23751.35 | 180 / 180 | 100% | 58.06 | 430 / 430 |
prostate | 100% | 16524.98 | 245 / 245 | 100% | 59.02 | 502 / 502 |
uterus | 100% | 23066.24 | 170 / 170 | 100% | 79.87 | 459 / 459 |
lung | 100% | 15885.68 | 578 / 578 | 100% | 61.56 | 1154 / 1155 |
bladder | 100% | 16354.62 | 21 / 21 | 100% | 60.38 | 503 / 504 |
brain | 100% | 10193.40 | 2630 / 2642 | 100% | 80.91 | 705 / 705 |
thymus | 100% | 20468.16 | 653 / 653 | 99% | 70.66 | 601 / 605 |
stomach | 100% | 11983.47 | 359 / 359 | 99% | 51.77 | 284 / 286 |
skin | 100% | 14447.07 | 1808 / 1809 | 99% | 69.11 | 468 / 472 |
intestine | 100% | 17583.60 | 966 / 966 | 99% | 48.71 | 521 / 527 |
kidney | 100% | 11502.55 | 89 / 89 | 99% | 49.18 | 889 / 901 |
pancreas | 99% | 7776.00 | 326 / 328 | 99% | 52.50 | 176 / 178 |
adrenal gland | 100% | 13190.90 | 258 / 258 | 97% | 35.32 | 222 / 230 |
liver | 100% | 6783.04 | 225 / 226 | 91% | 25.97 | 371 / 406 |
adipose | 100% | 15781.63 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 17061.67 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 50.21 | 29 / 29 |
muscle | 100% | 9310.83 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 16699.80 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 74.14 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 28.43 | 1 / 1 |
heart | 98% | 8303.43 | 841 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 94% | 32.41 | 75 / 80 |
peripheral blood | 78% | 6563.15 | 722 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0070828 | Biological process | heterochromatin organization |
GO_0097298 | Biological process | regulation of nucleus size |
GO_0042127 | Biological process | regulation of cell population proliferation |
GO_0006355 | Biological process | regulation of DNA-templated transcription |
GO_0071456 | Biological process | cellular response to hypoxia |
GO_0006334 | Biological process | nucleosome assembly |
GO_0016607 | Cellular component | nuclear speck |
GO_0005694 | Cellular component | chromosome |
GO_0000786 | Cellular component | nucleosome |
GO_0005634 | Cellular component | nucleus |
GO_0031491 | Molecular function | nucleosome binding |
GO_0003677 | Molecular function | DNA binding |
GO_0005515 | Molecular function | protein binding |
Gene name | HP1BP3 |
Protein name | Heterochromatin protein 1 binding protein 3 Heterochromatin protein 1-binding protein 3 Heterochromatin protein 1-binding protein 3 (Protein HP1-BP74) Alternative protein HP1BP3 |
Synonyms | hCG_38870 |
Description | FUNCTION: Component of heterochromatin that maintains heterochromatin integrity during G1/S progression and regulates the duration of G1 phase to critically influence cell proliferative capacity . Mediates chromatin condensation during hypoxia, leading to increased tumor cell viability, radio-resistance, chemo-resistance and self-renewal. . |
Accessions | ENST00000419948.5 Q5SSJ5 ENST00000312239.10 [Q5SSJ5-1] B0QZK5 B0QZK9 ENST00000375003.6 [Q5SSJ5-3] ENST00000375000.5 [Q5SSJ5-5] ENST00000414993.1 B0QZK6 B4E0N8 B0QZK8 ENST00000417710.5 ENST00000437575.5 ENST00000419490.5 B0QZK7 ENST00000443615.1 B0QZK4 L8E9W8 Q5SWC8 ENST00000424732.5 ENST00000438032.6 [Q5SSJ5-1] |